## Zhao Wang

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6687782/publications.pdf

Version: 2024-02-01

|          |                | 1163117      | 1125743        |
|----------|----------------|--------------|----------------|
| 31       | 206            | 8            | 13             |
| papers   | citations      | h-index      | g-index        |
|          |                |              |                |
|          |                |              |                |
|          |                |              |                |
| 31       | 31             | 31           | 390            |
| all docs | docs citations | times ranked | citing authors |
|          |                |              |                |

| #  | Article   | IF  | Citations |
|----|---|-----|-----------|
| 1  | Rituximab exposureâ€response in triweekly Râ€CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. Clinical and Translational Science, 2022, 15, 680-690.  | 3.1 | 3         |
| 2  | Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome. Frontiers in Pharmacology, 2022, 13, 788824.  | 3.5 | 1         |
| 3  | A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study. BMC Cancer, 2022, 22, 45.  | 2.6 | 1         |
| 4  | Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Leukemia and Lymphoma, 2021, 62, 571-580.                           | 1.3 | 3         |
| 5  | Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. Acta Pharmacologica Sinica, 2021, 42, 641-647.             | 6.1 | 4         |
| 6  | Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified. Frontiers in Oncology, 2021, 11, 607145.  | 2.8 | 6         |
| 7  | Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. Cancer Management and Research, 2021, Volume 13, 8831-8839.   | 1.9 | 2         |
| 8  | Platelet-derived alpha-granules are associated with inflammation in patients with NK/T-cell lymphoma-associated hemophagocytic syndrome. Cytokine, 2020, 126, 154878.   | 3.2 | 9         |
| 9  | A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment. Annals of Hematology, 2020, 99, 2811-2819.  | 1.8 | 5         |
| 10 | Long-Term Survival of Patients With Chemotherapy-Na $\tilde{A}$ -ve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen. Frontiers in Oncology, 2020, 10, 1011.                                | 2.8 | 9         |
| 11 | The derived neutrophilâ€ŧoâ€lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic Tâ€cell lymphoma. British Journal of Haematology, 2020, 189, 908-912.  | 2.5 | 16        |
| 12 | A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients. Leukemia and Lymphoma, 2020, 61, 1842-1849.                     | 1.3 | 3         |
| 13 | Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R. Lung Cancer, 2020, 144, 87-89.                             | 2.0 | 4         |
| 14 | A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy , Cancer Management and Research, 2020, Volume 12, 1981-1990.      | 1.9 | 3         |
| 15 | A prognostic index for nasalâ€type earlyâ€stage extranodal natural killer/Tâ€cell lymphoma: A multicenter study. American Journal of Hematology, 2019, 94, E122-E124.   | 4.1 | 7         |
| 16 | Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Cancer Research and Treatment, 2019, 51, 919-932. | 3.0 | 14        |
| 17 | PET/CT alone versus PET/CT and MRI-guided therapy in patients with upper aerodigestive tract natural killer/T-cell lymphoma, nasal type: A prospective study Journal of Clinical Oncology, 2019, 37, 7537-7537.                         | 1.6 | O         |
| 18 | A prospective study on the circulation and central nervous system after primary central nervous system B cell lymphoma treatment with rituximab Journal of Clinical Oncology, 2019, 37, e13518-e13518.                                  | 1.6 | 0         |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study. Leukemia and Lymphoma, 2018, 59, 2821-2828.                    | 1.3 | 11        |
| 20 | Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. Leukemia and Lymphoma, 2018, 59, 2911-2916.  | 1.3 | 11        |
| 21 | Randomized, open-label, phase â; trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma Journal of Clinical Oncology, 2018, 36, 7560-7560.           | 1.6 | 1         |
| 22 | Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial Journal of Clinical Oncology, 2018, 36, 7553-7553. | 1.6 | 0         |
| 23 | MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer. Cellular<br>Physiology and Biochemistry, 2017, 43, 2505-2515.  | 1.6 | 64        |
| 24 | Association between GSTP1 Ile105Val polymorphism and urinary system cancer risk: evidence from 51 studies. OncoTargets and Therapy, 2016, 9, 3565.  | 2.0 | 8         |
| 25 | Associations between <i>CYP1A1</i> rs1048943 A > G and rs4646903 T > C genetic variations and colorectal cancer risk: Proof from 26 case-control studies. Oncotarget, 2016, 7, 51365-51374.   | 1.8 | 15        |
| 26 | A prospective study of R-CHOP chemotherapy induced pulmonary pneumonia in diffuse large B-cell lymphoma Journal of Clinical Oncology, 2015, 33, e19508-e19508.  | 1.6 | 0         |
| 27 | Extranodal natural killer T-cell lymphoma, nasal-typeâ€"A new staging system from CSWOGâ€"A multicenter study Journal of Clinical Oncology, 2014, 32, 8552-8552.  | 1.6 | 3         |
| 28 | Prospetive study of thalidomide maintenance therapy in high-risk diffuse large B-cell lymphoma Journal of Clinical Oncology, 2014, 32, e19551-e19551.   | 1.6 | 1         |
| 29 | Perspective study of intensive therapy makes newly diagnosed distant metastatic nasopharyngeal cancer (mNPC) potential curable Journal of Clinical Oncology, 2014, 32, e17007-e17007.   | 1.6 | 0         |
| 30 | Prevention of thrombocytopenia using thrombopoietin in high-dose cytarabine treatment of non-Hodgkin lymphoma Journal of Clinical Oncology, 2014, 32, e19532-e19532.  | 1.6 | 2         |
| 31 | Early negative circulating EBV DNA as prediction of survival in extranodal NK/T-cell lymphoma, nasal type (ENKL) Journal of Clinical Oncology, 2014, 32, 8562-8562.   | 1.6 | O         |